BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34222137)

  • 21. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294.
    Xu Y; Yao Y; Gao P; Cui Y
    Biochem Biophys Res Commun; 2019 Jan; 509(1):138-142. PubMed ID: 30591218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression and patient's outcome?
    Szabo A; Gurlich R; Liberko M; Soumarova R; Vernerova Z; Mandys V; Popov A
    Neoplasma; 2020 Sep; 67(5):1170-1181. PubMed ID: 32567937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
    Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-24-3p Regulates Epithelial-Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression.
    Huang W; Lin T; Huang L; Wu J; Hong J; Qiu F; Tian Y; Wang Y
    Biochem Genet; 2023 Apr; 61(2):742-761. PubMed ID: 36114946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor suppressive role of miR-33a-5p in pancreatic ductal adenocarcinoma cells by directly targeting RAP2A.
    Lian Y; Jiang D; Sun J
    Cell Mol Biol Lett; 2021 Jun; 26(1):24. PubMed ID: 34090323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
    Yu Q; Xu C; Yuan W; Wang C; Zhao P; Chen L; Ma J
    Biomed Res Int; 2017; 2017():6495867. PubMed ID: 28466015
    [No Abstract]   [Full Text] [Related]  

  • 34. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
    Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
    PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
    Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
    Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
    Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
    J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
    Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
    Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Guo S; Qin H; Liu K; Wang H; Bai S; Liu S; Shao Z; Zhang Y; Song B; Xu X; Shen J; Zeng P; Shi X; Chen H; Gao S; Xu J; Pan Y; Xiong L; Li F; Zhang D; Jiao X; Jin G
    Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.